HUTCHMED (China) Limited (FRA:H7T1)

Market Cap	2.17B -3.0%
Revenue (ttm)	512.77M -1.4%
Net Income	397.55M
EPS	0.45
Shares Out	n/a
PE Ratio	5.45
Forward PE	11.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	103
Open	12.50
Previous Close	12.40
Day's Range	12.50 - 12.50
52-Week Range	10.40 - 15.90
Beta	n/a
RSI	53.44
Earnings Date	Mar 5, 2026

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 1,780
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: H7T1

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Financial numbers in USD